Recruiting
PHASE3
INTERVENTIONAL
NCT05827016
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Interventions
Name:
Iberdomide
Type:
DRUG
Description:
Specified dose on specified days
Name:
Lenalidomide
Type:
DRUG
Description:
Specified dose on specified days
Primary Outcomes
Measure:
Progression-free survival (PFS)
TimeFrame:
Up to 6 years
Description:
Trial Information
NCT ID
NCT05827016
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Bristol-Myers Squibb
Last Updated
December 15, 2025